Charles River Laboratories Intl. Inc vs Marvell Technology Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $232.3 (market cap $11.14B), while Marvell Technology Inc trades at $215.21 (market cap $195.25B). The key difference: Marvell Technology Inc is far larger — about 17.5× Charles River Laboratories Intl. Inc's market cap, and Marvell Technology Inc pays a 0.11% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | MRVL | |
|---|---|---|
Market Cap | $11.14B | $195.25B |
Sector | Health | Technology |
52-Week High | $233.60 | $316.43 |
52-Week Low | $145.57 | $62.31 |
Enterprise Value | $14.00B | $196.68B |
Dividend Yield | — | 0.11% |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
Marvell Technology (MRVL) trades at $217.53, down 7.75% over the past day, reflecting recent market volatility. The stock shows strong analyst support with an 82% buy rating and a consensus price target of $275.68, indicating significant upside potential. Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $0.80 surpassing the $0.798 estimate. However, the company reported a net loss of $885 million for 2025, though revenue grew to $5.77 billion. Technical indicators are bearish, with the price near key support at $213.
The outlook for MRVL is positive due to its positioning in custom AI chips and optical networking, with projected revenue growth to $8.7 billion in 2026. Risks include high valuation multiples (P/E of 74.75) and competitive pressures from peers like Nvidia and Broadcom. Investors should weigh the strong analyst optimism against fundamental challenges and market volatility.
Trailing returns across standard periods
Latest headlines on both assets
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →Marvell Technology is a leading fabless chipmaker focused on networking and storage applications. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical interconnections, application-specific integrated circuits (ASICs), and merchant silicon for Ethernet applications. The firm is an active acquirer, with five large acquisitions since 2017 helping it pivot out of legacy consumer applications to focus on the cloud and 5G markets.
Read more on MRVL →